OncRef

Clinical Trial: NCT04147351

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:National Taiwan University Hospital
Information Provided By:National Taiwan University Hospital
Last Update Posted:2026-04-21

Study Overview

Brief Summary

using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.

Official Title

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Conditions

NSCLC Stage IIIB~IV

Intervention / Treatment

  • Drug: Atezolizumab Injection; bevacizumab Injection

Other Study ID Numbers

  • 201908090MIFA

Start Date (Actual)

2020-04-10

Primary Completion Date (Actual)

2026-02-04

Study Completion Date (Actual)

2026-02-04

Enrollment (Actual)

22

Study Type

Interventional

Phase

Phase 2